公开(公告)号：US20240043527A1

公开(公告)日：2024-02-08

申请号：US17915567

申请日：2021-03-29

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Claudia Lindemann ,  Jan Diekmann ,  Kerstin Brettschneider ,  Hayat Bähr-Mahmud ,  Ursula Ellinghaus ,  Leyla Fischer ,  Christiane Stadler ,  Özlem Türeci

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/28 ,  A61P35/00 ,  C07K2317/522 ,  C07K2317/14

Abstract: The present disclosure provides RNA technologies for targeting Claudin-18.2 polypeptides. In some embodiments, such RNA technologies can be useful for treatment of diseases associated with positive expression of Claudin-18.2. For example, in some embodiments, such RNA technologies can be useful for treatment of Claudin-18.2 positive cancer, including, e.g, but not limited to biliary cancers, ovarian cancers, gastric cancers, gastro-esophageal cancers, pancreatic cancers. In some embodiments, such RNA technologies can be used in combination therapy (e.g, in combination with a chemotherapeutic agent).